Chen et al. confirmed that inhibiting p62 enhanced sensitivity to cisplatin in NPC cells44, our data present new evidence as well as a regulatory mechanism for p62‐mediated drug resistance in NPC. The gene discussed is IGF2BP2; the disease is nasopharyngeal carcinoma.